X4 Pharmaceuticals, Inc. (XFOR)
NASDAQ: XFOR · Real-Time Price · USD
4.430
+0.140 (3.26%)
At close: May 8, 2026, 4:00 PM EDT
4.350
-0.080 (-1.81%)
After-hours: May 8, 2026, 7:37 PM EDT
X4 Pharmaceuticals Employees
X4 Pharmaceuticals had 45 employees as of December 31, 2025. The number of employees decreased by 98 or -68.53% compared to the previous year.
Employees
45
Change (1Y)
-98
Growth (1Y)
-68.53%
Revenue / Employee
$200,311
Profits / Employee
-$2,216,044
Market Cap
402.77M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 45 | -98 | -68.53% |
| Dec 31, 2024 | 143 | 50 | 53.76% |
| Dec 31, 2023 | 93 | 23 | 32.86% |
| Dec 31, 2022 | 70 | -13 | -15.66% |
| Dec 31, 2021 | 83 | 11 | 15.28% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Rocket Pharmaceuticals | 202 |
| Puma Biotechnology | 179 |
| Nautilus Biotechnology | 130 |
| Invivyd | 122 |
| Niagen Bioscience | 117 |
| Lineage Cell Therapeutics | 77 |
| Surrozen | 44 |
| Opus Genetics | 28 |
XFOR News
- 1 day ago - X4 Pharmaceuticals reports Q1 EPS (16c), consensus (20c) - TheFly
- 2 days ago - X4 Pharmaceuticals files $300M mixed securities shelf - TheFly
- 2 days ago - X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 9 days ago - X4 Pharmaceuticals announces EC approval of Xolremdi - TheFly
- 9 days ago - X4 Pharmaceuticals Announces European Commission Approval of XOLREMDI® (Mavorixafor), the First and Only Authorized Treatment for Patients with WHIM Syndrome in the European Union - GlobeNewsWire
- 5 weeks ago - X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 weeks ago - X4 Pharmaceuticals reports Q4 EPS (22c), consensus (35c) - TheFly
- 7 weeks ago - X4 Pharmaceuticals sees cash runway through 2028 - TheFly